Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL736881 | 0.90 | HRH2 (0.32) | HRH3HRH2HRH1 | |
| SCHEMBL4706871 | 0.90 | HRH2 (0.32) | HRH3HRH2HRH1 | |
| SCHEMBL2013037 | 0.90 | HRH2 (0.32) | HRH3HRH2HRH1 | |
| SCHEMBL23828674 | 0.79 | HRH3 (0.44) | LTA4HHRH3HRH2HRH1MAOB | |
| SCHEMBL772272 | 0.79 | ACHE (0.37) | LTA4HHRH3HRH2HRH1MAOB | |
| SCHEMBL772273 | 0.79 | ACHE (0.37) | LTA4HHRH3HRH2HRH1MAOB | |
| SCHEMBL19074420 | 0.77 | HRH3 (0.39) | LTA4HHRH3HRH2HRH1MAOB | |
| SCHEMBL1286680 | 0.77 | HRH3 (0.39) | LTA4HHRH3HRH2HRH1MAOB | |
| SCHEMBL4088693 | 0.75 | LTA4H (0.38) | LTA4HHRH3HRH2HRH1MAOB | |
| SCHEMBL8237729 | 0.75 | LTA4H (0.38) | LTA4HHRH3HRH2HRH1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102781919-A | Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7 | HYBRIGENICS SA | 2012-11-14 | — | — | CN | claimed |
| US-20230364053-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PROSTATE CANCER OR BREAST CANCER | TOKYO METROPOLITAN GERIATRIC HOSPITAL AND INSTITUTE OF GERONTOLOGY (JP) | 2023-11-16 | — | — | US | disclosed |
| EP-4223293-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PROSTATE CANCER OR BREAST CANCER | Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology (JP) | 2023-08-09 | — | — | EP | disclosed |
| EP-2139472-B1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2016-01-13 | — | — | EP | disclosed |
| CN-102781919-A | Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7 | HYBRIGENICS SA | 2012-11-14 | — | — | CN | disclosed |
| US-8288432-B2 | Tetrahydroindole derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2012-10-16 | — | — | US | disclosed |
| US-7960394-B2 | 3,8-dimethyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]-4(3H)-quinazolinone; 6-chloro-3-methyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]pyrido[3,4-d]-pyrimidin-4(3H)-one; 2-[4-(1-cyclopentyl-4-piperidinyloxy)phenyl]-3-methylpyrido[2,3-d]-pyrimidin-4(3H)-one; treats metabolic, nervous system, vascular disorders | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-7790720-B2 | Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses | UCB PHARMA, S.A. (BE) | 2010-09-07 | — | — | US | disclosed |
| US-20100120749-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2010-05-13 | — | — | US | disclosed |
| EP-2139472-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2010-01-06 | — | — | EP | disclosed |
| WO-2006103045-A1 | COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB PHARMA S.A. (BE) | 2006-10-05 | — | — | WO | disclosed |
| EP-1136474-B1 | 1-Acetyl-5-bromo-4,6-dimethylindoline | SANKYO CO (JP) | 2003-11-26 | — | — | EP | disclosed |
| EP-0782986-B1 | NOVEL HETEROCYCLIC DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL USE THEREOF | SANKYO CO (JP) | 2003-07-02 | — | — | EP | disclosed |
| US-6489475-B2 | ENZYME INHIBITOR; LIPOPEROXIDATION INHIBITOR | SANKYO COMPANY, LIMITED (JP) | 2002-12-03 | — | — | US | disclosed |
| US-6414012-B1 | CARDIOVASCULAR DISORDERS; ANTICHOLESTEROL AGENTS | SANKYO COMPANY, LIMITED (JP) | 2002-07-02 | — | — | US | disclosed |
| EP-1136474-A1 | 1-Acetyl-5-bromo-4,6-dimethyl-indoline | SANKYO COMPANY LIMITED (JP) | 2001-09-26 | — | — | EP | disclosed |
| US-20010014740-A1 | Enzyme inhibitor; lipoperoxidation inhibitor | MATSUI HIROSHI (JP) | 2001-08-16 | — | — | US | disclosed |
| US-6127403-A | AN ENZYME INHIBITOR FOR TREATING ARTERIOSCLEROTIC LESIONS OF ARTERIOSCLEROSIS, HYPERLIPEMIA AND DIABETES, AS WELL AS ISCHEMIC DISEASES OF BRAIN, HEART | SANKYO COMPANY, LTD. (JP) | 2000-10-03 | — | — | US | disclosed |
| US-5990150-A | ACYLCOENZYME A:CHOLESTEROL ACYLTRANSFERASE (ACAT) INHIBITORS AND LIPOPEROXIDATION INHIBITORY ACTIVITY; ANTILIPEMIA; ARTERIOSCLEROSIS; ANTICHOLESTEROL AGENTS; ANTIISCHEMIC AGENTS; SIDE EFFECT REDUCTION | SANKYO COMPANY, LTD. (JP) | 1999-11-23 | — | — | US | disclosed |
| EP-0782986-A1 | NOVEL HETEROCYCLIC DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 1997-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010014740-A1 | Enzyme inhibitor; lipoperoxidation inhibitor | ACAT2, ACOX1, ACAT1 | LTA4H 162/4885HRH3 4682/4885HRH2 3443/4885 |
| US-20100120749-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | CYBB, NQO1, NOX4 | LTA4H 329/4885HRH3 742/4885HRH2 442/4885 |
| US-20230364053-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PROSTATE CANCER OR BREAST CANCER | AR, NR5A1, CYP17A1 | LTA4H 2477/4885HRH3 2263/4885HRH2 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.